Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 0.71 |
| ▸ | LMNA | P02545 | 7/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.71 |
| ▸ | MAPT | P10636 | 5/20 | 0.71 |
| ▸ | SERPINA6 | P08185 | 5/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.71 |
| ▸ | TSHR | P16473 | 4/20 | 0.71 |
| ▸ | SHBG | P04278 | 4/20 | 0.71 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.71 |
| ▸ | PGR | P06401 | 3/20 | 0.71 |
| ▸ | AR | P10275 | 3/20 | 0.71 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.71 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.71 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.71 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.71 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.71 |
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7992724 | 1.00 | CYP3A4 (0.71) | CYP3A4LMNASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL4747201 | 1.00 | CYP3A4 (0.71) | CYP3A4LMNASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL23748331 | 1.00 | CYP3A4 (0.71) | CYP3A4LMNASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL6053061 | 0.91 | CYP19A1 (0.66) | CYP3A4LMNASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL3633040 | 0.90 | CYP19A1 (0.65) | CYP3A4LMNASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL9640298 | 0.89 | SMN1; SMN2 (0.71) | CYP3A4LMNASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL28665872 | 0.88 | ALDH1A1 (0.69) | CYP3A4LMNASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL29127389 | 0.88 | CYP3A4 (0.69) | CYP3A4LMNASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL527920 | 0.86 | CYP19A1 (0.72) | CYP3A4LMNAMAPTSERPINA6MAPK1 | |
| SCHEMBL3836278 | 0.86 | CYP19A1 (0.72) | CYP3A4LMNAMAPTSERPINA6MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114533741-A | Antiviral use of progesterone | 河南农业大学 | 2022-05-27 | — | — | CN | claimed |
| CN-113980079-A | Synthesis method of 10 beta-hydroxy levonorgestrel | 湖南科益新生物医药有限公司 | 2022-01-28 | — | — | CN | claimed |
| CN-113956316-A | Preparation method of 10 beta-hydroxy levonorgestrel | 湖南科益新生物医药有限公司 | 2022-01-21 | — | — | CN | claimed |
| CN-109415402-B | Quantitative analysis of progesterone metabolites for prediction of spontaneous preterm birth | 印第安纳大学研究与技术公司 | 2021-10-19 | — | — | CN | claimed |
| CN-109415402-A | For predicting the quantitative analysis of the progesterone metabolite of spontaneous pre-term | 印第安纳大学研究与技术公司 | 2019-03-01 | — | — | CN | claimed |
| US-20160038536-A1 | PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF TRAUMA-INDUCED NEUROPATHOLOGY AND NEURODEGENERATION | SAPNA LIFE SCIENCES CORPORATION (CA) | 2016-02-11 | — | — | US | claimed |
| WO-2014107794-A1 | FORMULATIONS AND METHODS FOR THEIR USE IN TREATMENT OF NEUROPATHOLOGY AND NEURODEGENERATION AS A RESULT OF TRAUMATIC INJURY | SAPNA LIFE SCIENCES CORP. (CA) | 2014-07-17 | — | — | WO | claimed |
| WO-2014108808-A2 | PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF TRAUMA-INDUCED NEUROPATHOLOGY AND NEURODEGENERATION | HENRY JAMES LORNE (CA) | 2014-07-17 | — | — | WO | claimed |
| WO-2014108809-A2 | MULTIPLE-COMPONENT PHARMACEUTICAL FORMULATIONS AND METHODS FOR THEIR USE IN TREATING NEUROPATHOLOGY AND NEURODEGENERATION CAUSED BY TRAUMATIC INJURY | HENRY JAMES LORNE (CA) | 2014-07-17 | — | — | WO | claimed |
| US-20140194394-A1 | TWO-COMPONENT FORMULATIONS, METHODS AND PROCEDURES TO PREVENT OR REDUCE TRAUMA-INDUCED NEUROPATHOLOGY AND NEURODEGENERATION | SAPNA LIFE SCIENCES CORPORATION (CA) | 2014-07-10 | — | — | US | claimed |
| US-20140194397-A1 | MULTIPLE-COMPONENT PHARMACEUTICAL FORMULATIONS AND METHODS FOR THEIR USE IN TREATING NEUROPATHOLOGY AND NEURODEGENERATION CAUSED BY TRAUMATIC INJURY | SAPNA LIFE SCIENCES CORPORATION (CA) | 2014-07-10 | — | — | US | claimed |
| US-20140193523-A1 | PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF TRAUMA-INDUCED NEUROPATHOLOGY AND NEURODEGENERATION | SAPNA LIFE SCIENCES CORPORATION (CA) | 2014-07-10 | — | — | US | claimed |
| EP-1940414-A2 | ANTI MINERALOCORTICOID THERAPY OF INFECTION | Prendergast, Patrick T. (AU) | 2008-07-09 | — | — | EP | claimed |
| WO-2007049265-A2 | ANTI MINERALOCORTICOID THERAPY OF INFECTION | PRENDERGAST PATRICK T (AU) | 2007-05-03 | — | — | WO | claimed |
| EP-0758229-A1 | TOPICAL POLYMERIC DRUG DELIVERY SYSTEM | MERCK FROSST CANADA INC. (CA) | 1997-02-19 | — | — | EP | claimed |
| WO-1995030409-A1 | TOPICAL POLYMERIC DRUG DELIVERY SYSTEM | MERCK FROSST CANADA INC. (CA) | 1995-11-16 | — | — | WO | claimed |
| CN-1088778-A | Based on the drug delivery system of solubility parameters and the method for change medicine saturated concentration | NOVEN PHARMA (US) | 1994-07-06 | — | — | CN | claimed |
| EP-0238545-A1 | C 20? THROUGH C 26? AMINO STEROIDS. | UPJOHN CO (US) | 1987-09-30 | — | — | EP | claimed |
| WO-1987001706-A2 | C20 THROUGH C26 AMINO STEROIDS | THE UPJOHN COMPANY (US) | 1987-03-26 | — | — | WO | claimed |
| CN-116568682-A | Novel compounds for the treatment of angiotensin II related diseases | 维科尔药物公司 | 2023-08-08 | — | — | CN | disclosed |
| CN-114836387-B | 11-alpha hydroxyprogesterone monoclonal antibody hybridoma cell strain and application thereof | 江南大学 | 2023-08-04 | — | — | CN | disclosed |
| WO-2023097328-A2 | FLAVANOID CONTAINING COMPOSITIONS AND METHODS OF USE THEREOF FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2023-06-01 | — | — | WO | disclosed |
| CN-115927405-A | Gene sequence for coding P450 enzyme and cytochrome P450 reductase derived from fusarium graminearum and recombinant strain thereof | 湖北大学 | 2023-04-07 | — | — | CN | disclosed |
| CN-115843244-A | Novel capsule compositions for oral administration | 维科尔药物公司 | 2023-03-24 | — | — | CN | disclosed |
| CN-115811971-A | Novel delayed release compositions for oral administration | 维科尔药物公司 | 2023-03-17 | — | — | CN | disclosed |
| CN-115697309-A | Novel dry powder compositions for oral administration | 维科尔药物公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-115666557-A | Imidazoyl thiophene sulfonyl carbamates for the treatment of angiotensin II related diseases | 维科尔药物公司 | 2023-01-31 | — | — | CN | disclosed |
| CN-115605201-A | New use of angiotensin II type 2 receptor agonists | 维科尔药物公司（SE） | 2023-01-13 | — | — | CN | disclosed |
| CN-115605265-A | Novel compounds for the treatment and/or prevention of diseases, disorders or conditions associated with angiotensin ii | 维科尔药物公司（SE） | 2023-01-13 | — | — | CN | disclosed |
| CN-114836387-A | 11-alpha hydroxyprogesterone monoclonal antibody hybridoma cell strain and application thereof | 江南大学 | 2022-08-02 | — | — | CN | disclosed |
| US-11357793-B2 | Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration | SAPNA LIFE SCIENCES CORPORATION (CA) | 2022-06-14 | — | — | US | disclosed |
| CN-114533741-A | Antiviral use of progesterone | 河南农业大学 | 2022-05-27 | — | — | CN | disclosed |
| CN-114206396-A | Methods and compositions for attenuating an immune response against an antiviral transfer vector | 西莱克塔生物科技公司 | 2022-03-18 | — | — | CN | disclosed |
| CN-114207440-A | PEGylated uricase formulations and dosages | 西莱克塔生物科技公司 | 2022-03-18 | — | — | CN | disclosed |
| CN-113980079-A | Synthesis method of 10 beta-hydroxy levonorgestrel | 湖南科益新生物医药有限公司 | 2022-01-28 | — | — | CN | disclosed |
| CN-107106509-B | Drug delivery system for delivering acid sensitive drugs | 帝斯曼知识产权资产管理有限公司 | 2021-11-30 | — | — | CN | disclosed |
| EP-3911360-A1 | METHODS OF MODULATING CORTICOSTEROID RESPONSE | Mallinckrodt Ard IP Unlimited Company (IE) | 2021-11-24 | — | — | EP | disclosed |
| CN-107056864-B | Synthesis method of fluoprogesterone acetate | 浙江仙居仙乐药业有限公司 | 2021-10-19 | — | — | CN | disclosed |
| CN-109415402-B | Quantitative analysis of progesterone metabolites for prediction of spontaneous preterm birth | 印第安纳大学研究与技术公司 | 2021-10-19 | — | — | CN | disclosed |
| CN-113390989-A | Detection method of veterinary drug residues in fish | 成都市食品药品检验研究院 | 2021-09-14 | — | — | CN | disclosed |
| US-11033510-B2 | Anti-inflammatory pharmaceutical compositions and methods of administration | LANCE L. GOOBERMAN (US) | 2021-06-15 | — | — | US | disclosed |
| CN-112552364-A | Novel 11 beta-hydroxysteroid compounds for use in mitochondrial biogenesis and diseases associated with mitochondrial dysfunction or depletion | 司菲埃拉制药私人有限公司 | 2021-03-26 | — | — | CN | disclosed |
| CN-110229838-B | Method for obtaining hydroxylated compound by biotransformation of steroid compound | 浙江理工大学 | 2021-01-08 | — | — | CN | disclosed |
| CN-112198265-A | Pretreatment method, detection method and kit for simultaneously detecting multiple steroid hormones in blood sample | 广州金域医学检验中心有限公司 | 2021-01-08 | — | — | CN | disclosed |
| US-20200289408-A1 | SOLID IMPLANT FORMULATION FOR DRUG DELIVERY | MALLON ANDREW (US) | 2020-09-17 | — | — | US | disclosed |
| CN-111491625-A | Monosodium urate for treating gout | 马克·霍伯 | 2020-08-04 | — | — | CN | disclosed |
| WO-2020150738-A1 | METHODS OF MODULATING CORTICOSTEROID RESPONSE | MALLINCKRODT ARD IP LIMITED (IE) | 2020-07-23 | — | — | WO | disclosed |
| US-20200138725-A1 | ANTI-INFLAMMATORY PHARMACEUTICAL COMPOSITIONS AND METHODS OF ADMINISTRATION | GOOBERMAN LANCE L (US) | 2020-05-07 | — | — | US | disclosed |
| US-10568842-B2 | Anti-inflammatory pharmaceutical compositions and methods of administration | LANCE L. GOOBERMAN (US) | 2020-02-25 | — | — | US | disclosed |
| CN-110612122-A | Methods and compositions related to combination therapy with anti-inflammatory agents and synthetic nanocarriers comprising immunosuppressants | 西莱克塔生物科技公司 | 2019-12-24 | — | — | CN | disclosed |
| EP-3554363-A1 | INGESTIBLE DEVICE AND ASSOCIATED METHODS | Progenity, Inc. (US) | 2019-10-23 | — | — | EP | disclosed |
| US-20190125789-A1 | PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF TRAUMA-INDUCED NEUROPATHOLOGY AND NEURODEGENERATION | SAPNA LIFE SCIENCES CORPORATION (CA) | 2019-05-02 | — | — | US | disclosed |
| US-20190083413-A1 | Anti-Inflammatory Pharmaceutical Compositions and Methods of Administration | GOOBERMAN LANCE L (US) | 2019-03-21 | — | — | US | disclosed |
| CN-109415402-A | For predicting the quantitative analysis of the progesterone metabolite of spontaneous pre-term | 印第安纳大学研究与技术公司 | 2019-03-01 | — | — | CN | disclosed |
| US-10201569-B2 | Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration | SAPNA LIFE SCIENCES CORPORATION (CA) | 2019-02-12 | — | — | US | disclosed |
| US-20190038637-A1 | Use of Hydroxyprogesterone Derivatives for Enhanced Health and Physical Performance II | MARCHEWITZ ERIC (US) | 2019-02-07 | — | — | US | disclosed |
| WO-2019010230-A1 | COMPOSITIONS FOR DRUG DELIVERY | TIOGA RESEARCH, INC. (US) | 2019-01-10 | — | — | WO | disclosed |
| WO-2018111326-A1 | METHODS AND INGESTIBLE DEVICES FOR THE REGIO-SPECIFIC RELEASE OF IMMUNOSUPPRESSANTS AT THE SITE OF GASTROINTESTINAL TRACT DISEASE | PROGENITY INC. (US) | 2018-06-21 | — | — | WO | disclosed |
| WO-2018112441-A1 | INGESTIBLE DEVICE AND ASSOCIATED METHODS | PROGENITY INC. (US) | 2018-06-21 | — | — | WO | disclosed |
| WO-2018112425-A1 | INGESTIBLE DEVICE AND ASSOCIATED METHODS | PROGENITY INC. (US) | 2018-06-21 | — | — | WO | disclosed |
| WO-2018112389-A1 | INGESTIBLE DEVICE AND ASSOCIATED METHODS | PROGENITY INC. (US) | 2018-06-21 | — | — | WO | disclosed |
| CN-107029453-A | A kind of 17 α hydroxyprogesterone molecularly imprinted solid phase extraction columns and preparation method thereof and the method for detecting 17 α hydroxyprogesterones | 无限极（中国）有限公司 | 2017-08-11 | — | — | CN | disclosed |
| CN-106344233-A | Sleeves for expandable medical devices | W.L.戈尔及同仁股份有限公司 | 2017-01-25 | — | — | CN | disclosed |
| EP-3107569-A1 | ANTI-ACTH ANTIBODIES AND USE THEREOF | Alder Biopharmaceuticals, Inc. (US) | 2016-12-28 | — | — | EP | disclosed |
| US-20160038536-A1 | PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF TRAUMA-INDUCED NEUROPATHOLOGY AND NEURODEGENERATION | SAPNA LIFE SCIENCES CORPORATION (CA) | 2016-02-11 | — | — | US | disclosed |
| EP-2948152-A2 | NOVEL COMPOUNDS OF 11BETA-HYDROXY-STEROIDS FOR USE IN MITOCHONDRIA BIOGENESIS AND DISEASES ASSOCIATED WITH MITOCHONDRIAL DYSFUNCTION OR DEPLETION | Sphaera Pharma Pvt. Ltd. (IN) | 2015-12-02 | — | — | EP | disclosed |
| US-20150313914-A1 | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING HYPOGONADISM | BESINS HEALTHCARE INC (US) | 2015-11-05 | — | — | US | disclosed |
| WO-2015161078-A1 | METHODS FOR COMPREHENSIVE PROFILING OF STEROID METABOLOME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-10-22 | — | — | WO | disclosed |
| US-9132089-B2 | Pharmaceutical composition and method for treating hypogonadism | BESINS HEALTHCARE INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-9125816-B2 | Pharmaceutical composition and method for treating hypogonadism | BESINS HEALTHCARE INC. (US) | 2015-09-08 | — | — | US | disclosed |
| WO-2015127288-A1 | ANTI-ACTH ANTIBODIES AND USE THEREOF | ALDER BIOPHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | WO | disclosed |
| US-20140309186-A1 | Metabolomics-Based Identification of Disease-Causing Agents | GEORGIA TECH RESEARCH CORPORATION | 2014-10-16 | — | — | US | disclosed |
| WO-2014115167-A2 | NOVEL COMPOUNDS OF 11BETA-HYDROXY-STEROIDS FOR USE IN MITOCHONDRIA BIOGENESIS AND DISEASES ASSOCIATED WITH MITOCHONDRIAL DYSFUNCTION OR DEPLETION | SPHAERA PHARMA PVT. LTD. (IN) | 2014-07-31 | — | — | WO | disclosed |
| WO-2014107794-A1 | FORMULATIONS AND METHODS FOR THEIR USE IN TREATMENT OF NEUROPATHOLOGY AND NEURODEGENERATION AS A RESULT OF TRAUMATIC INJURY | SAPNA LIFE SCIENCES CORP. (CA) | 2014-07-17 | — | — | WO | disclosed |
| WO-2014108809-A2 | MULTIPLE-COMPONENT PHARMACEUTICAL FORMULATIONS AND METHODS FOR THEIR USE IN TREATING NEUROPATHOLOGY AND NEURODEGENERATION CAUSED BY TRAUMATIC INJURY | HENRY JAMES LORNE (CA) | 2014-07-17 | — | — | WO | disclosed |
| WO-2014108808-A2 | PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF TRAUMA-INDUCED NEUROPATHOLOGY AND NEURODEGENERATION | HENRY JAMES LORNE (CA) | 2014-07-17 | — | — | WO | disclosed |
| US-20140194397-A1 | MULTIPLE-COMPONENT PHARMACEUTICAL FORMULATIONS AND METHODS FOR THEIR USE IN TREATING NEUROPATHOLOGY AND NEURODEGENERATION CAUSED BY TRAUMATIC INJURY | SAPNA LIFE SCIENCES CORPORATION (CA) | 2014-07-10 | — | — | US | disclosed |
| US-20140193523-A1 | PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF TRAUMA-INDUCED NEUROPATHOLOGY AND NEURODEGENERATION | SAPNA LIFE SCIENCES CORPORATION (CA) | 2014-07-10 | — | — | US | disclosed |
| US-20130303501-A1 | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING HYPOGONADISM | BESINS HEALTHCARE LUXEMBOURG SARL (LU) | 2013-11-14 | — | — | US | disclosed |
| US-20130261097-A1 | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING HYPOGONADISM | DUDLEY ROBERT E (US) | 2013-10-03 | — | — | US | disclosed |
| EP-2606352-A1 | ASSAY FOR ANALYTES USING MULTIPLE RECEPTORS | Siemens Healthcare Diagnostics Inc. (US) | 2013-06-26 | — | — | EP | disclosed |
| US-20120277201-A1 | Use of hydroxyprogesterone derivatives for enhancing health and physical performance | MARCHEWITZ ERIC D (US) | 2012-11-01 | — | — | US | disclosed |
| WO-2012024416-A1 | ASSAY FOR ANALYTES USING MULTIPLE RECEPTORS | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2012-02-23 | — | — | WO | disclosed |
| US-20110246081-A1 | Metabolomics-Based Identification of Disease-Causing Agents | GEORGIA TECH RESEARCH CORPORATION (US) | 2011-10-06 | — | — | US | disclosed |
| CN-101087793-B | Novel substituted thiophenepyrimidinone derivatives as inhibitors of 17beta-hydroxysteroid dehydrogenase | SOLVAY PHARM BV | 2011-09-07 | — | — | CN | disclosed |
| US-20110201586-A1 | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING HYPOGONADISM | DUDLEY ROBERT E | 2011-08-18 | — | — | US | disclosed |
| US-20110172196-A1 | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING HYPOGONADISM | DUDLEY ROBERT E | 2011-07-14 | — | — | US | disclosed |
| EP-2281553-A2 | Pharmaceutical composition and method for treating hypogonadism | Unimed Pharmaceuticals, LLC (US) | 2011-02-09 | — | — | EP | disclosed |
| EP-0934743-B2 | Use of a wax microdispersion in cosmetic or dermatological compositions | OREAL (FR) | 2010-11-24 | — | — | EP | disclosed |
| EP-1519943-B1 | HORMONE-BASED NITROGEN MONOXIDE DONOR COMPOUNDS AND USE THEREOF IN OBSTETRICS AND GYNECOLOGY | EFFIK (FR) | 2010-04-28 | — | — | EP | disclosed |
| WO-2010015036-A1 | BIOLOGICAL APPLICATIONS OF STEROID BINDING DOMAINS | HOVENS CHRISTOPHER (AU) | 2010-02-11 | — | — | WO | disclosed |
| EP-2142194-A1 | MINERALOCORTICOID RECEPTOR ANTAGONISTS | N.V. Organon (NL) | 2010-01-13 | — | — | EP | disclosed |
| WO-2009088414-A2 | ORAL PHARMACEUTICAL DOSAGE FORMS | DURECT CORPORATION (US) | 2009-07-16 | — | — | WO | disclosed |
| CN-100502876-C | Thiophenepyrimidinones as 17-beta-hydroxysteroid dehydrogenase inhibitors | SOLVAY PHARM BV (NL) | 2009-06-24 | — | — | CN | disclosed |
| EP-2070517-A2 | Pharmaceutical composition and method for treating hypogonadism | Unimed Pharmaceuticals Inc. (US) | 2009-06-17 | — | — | EP | disclosed |
| WO-2009052186-A1 | METABOLOMICS-BASED IDENTIFICATION OF DISEASE-CAUSING AGENTS | GEORGIA TECH RESEARCH CORPORATION (US) | 2009-04-23 | — | — | WO | disclosed |
| EP-1976997-B1 | PROCESS FOR THE PREPARATION OF 11BETA-HYDR0XY-9BETA,10ALPHA-STEROIDS EMPLOYING AMYCOLATOPSIS MEDITERRANEI CELLS | SOLVAY PHARM GMBH (DE) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008119918-A1 | MINERALOCORTICOID RECEPTOR ANTAGONISTS | N.V. ORGANON (NL) | 2008-10-09 | — | — | WO | disclosed |
| EP-1976997-A1 | PROCESS FOR THE PREPARATION OF 11BETA-HYDR0XY-9BETA, 10ALPHA -STEROIDS EMPLOYING AMYCOLATOPSIS MEDITERRANEI CELLS | Solvay Pharmaceuticals GmbH (DE) | 2008-10-08 | — | — | EP | disclosed |
| EP-1896042-A4 | METHODS AND REAGENTS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | COMBINATORX INC (US) | 2008-09-17 | — | — | EP | disclosed |
| EP-1896042-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | CombinatoRx, Incorporated (US) | 2008-03-12 | — | — | EP | disclosed |
| CN-101087793-A | Novel substituted thiophenepyrimidinone derivatives as inhibitors of 17beta-hydroxysteroid dehydrogenase | SOLVAY PHARM BV (DE) | 2007-12-12 | — | — | CN | disclosed |
| WO-2007082891-A1 | PROCESS FOR THE PREPARATION OF 11BETA-HYDR0XY-9BETA, 10ALPHA -STEROIDS EMPLOYING AMYCOLATOPSIS MEDITERRANEI CELLS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-07-26 | — | — | WO | disclosed |
| WO-2006138372-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2006-12-28 | — | — | WO | disclosed |
| EP-1506014-A4 | PROCESS FOR THE PREPARATION AND ACTIVATION OF SUBSTANCES AND A MEANS OF PRODUCING SAME | CHEMSTOP PTY LTD (AU) | 2006-09-20 | — | — | EP | disclosed |
| CN-1791412-A | Novel compounds and their use in therapy | SOLVAY PHARM GMBH (NL) | 2006-06-21 | — | — | CN | disclosed |
| CN-1784234-A | Thiophenepyrimidinones as 17-beta-hydroxysteroid dehydrogenase inhibitors | SOLVAY PHARM BV (NL) | 2006-06-07 | — | — | CN | disclosed |
| CN-1681557-A | Methods for treating carbonic anhydrase mediated disorders | PHARMACIA CORP (US) | 2005-10-12 | — | — | CN | disclosed |
| US-20050142173-A1 | Pharmaceutical composition and method for treating hypogonadism | LABORATOIRES BESINS INTERNATIONAL, SAS (FR) | 2005-06-30 | — | — | US | disclosed |
| EP-1519943-A2 | HORMONE-BASED NITROGEN MONOXIDE DONOR COMPOUNDS AND USE THEREOF IN OBSTETRICS AND GYNECOLOGY | Effik (FR) | 2005-04-06 | — | — | EP | disclosed |
| WO-2005016243-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND AN ANTIOXIDANT AGENT FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | PHARMACIA CORPORATION (US) | 2005-02-24 | — | — | WO | disclosed |
| EP-1506014-A1 | PROCESS FOR THE PREPARATION AND ACTIVATION OF SUBSTANCES AND A MEANS OF PRODUCING SAME | CHEMSTOP PTY LTD (AU) | 2005-02-16 | — | — | EP | disclosed |
| EP-1487859-A2 | PROCESS TO PREPARE EPLERENONE | PHARMACIA & UPJOHN COMPANY (US) | 2004-12-22 | — | — | EP | disclosed |
| EP-1478396-A1 | PROCESS FOR THE PREPARATION OF A NUTRIENT FORMULATION | CHEMSTOP PTY LTD (AU) | 2004-11-24 | — | — | EP | disclosed |
| EP-0934743-B1 | Use of a wax microdispersion in cosmetic or dermatological compositions | OREAL (FR) | 2004-06-02 | — | — | EP | disclosed |
| EP-1409536-A2 | HUMAN PROTEINS AND NUCLEIC ACIDS ENCODING SAME | Curagen Corporation (US) | 2004-04-21 | — | — | EP | disclosed |
| CN-1473044-A | Inhalative solution formulation containing tiotropium salt | ���ָ��Ӣ��ķ�������Ϲ�˾ | 2004-02-04 | — | — | CN | disclosed |
| WO-2004007522-A2 | HORMONE-BASED NITROGEN MONOXIDE DONOR COMPOUNDS AND USE THEREOF IN OBSTETRICS AND GYNECOLOGY | EFFIK (FR) | 2004-01-22 | — | — | WO | disclosed |
| US-20040010119-A1 | Novel proteins and nucleic acids encoding same | CURAGEN CORPORATION | 2004-01-15 | — | — | US | disclosed |
| EP-1378749-A1 | SCREENING METHOD | Takeda Chemical Industries, Ltd. (JP) | 2004-01-07 | — | — | EP | disclosed |
| US-20030232072-A1 | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING HYPOGONADISM | LABORATOIRES BESINS INTERNATIONAL, SAS (FR) | 2003-12-18 | — | — | US | disclosed |
| WO-2003097095-A1 | PROCESS FOR THE PREPARATION AND ACTIVATION OF SUBSTANCES AND A MEANS OF PRODUCING SAME | CHEMSTOP PTY LTD (AU) | 2003-11-27 | — | — | WO | disclosed |
| EP-1356286-A2 | METHOD FOR ESTIMATING METABOLIC FUNCTION OF XENOBIOTIC AND INDUCTION THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2003-10-29 | — | — | EP | disclosed |
| WO-2003082895-A2 | PROCESS TO PREPARE EPLERENONE | PHARMACIA & UPJOHN COMPANY (US) | 2003-10-09 | — | — | WO | disclosed |
| WO-2003063900-A1 | PROCESS FOR THE PREPARATION OF A NUTRIENT FORMULATION | CHEMSTOP PTY LTD (AU) | 2003-08-07 | — | — | WO | disclosed |
| EP-1313482-A1 | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING HYPOGONADISM | Unimed Pharmaceuticals Inc. (US) | 2003-05-28 | — | — | EP | disclosed |
| US-20030050292-A1 | Pharmaceutical composition and method for treating hypogonadism | LABORATOIRES BESINS INTERNATIONAL, SAS (FR) | 2003-03-13 | — | — | US | disclosed |
| EP-1269984-A1 | Cosmetic and/or dermatological andor pharmaceutical composition for topical application containing at least one compound inhibiting 3-beta-HSD enzyme | L'OREAL (FR) | 2003-01-02 | — | — | EP | disclosed |
| WO-2002098917-A2 | HUMAN PROTEINS AND NUCLEIC ACIDS ENCODING SAME | CURAGEN CORPORATION (US) | 2002-12-12 | — | — | WO | disclosed |
| US-20020183296-A1 | Pharmaceutical composition and method for treating hypogonadism | LABORATOIRES BESINS INTERNATIONAL, SAS (FR) | 2002-12-05 | — | — | US | disclosed |
| WO-2002040995-A2 | METHOD FOR ESTIMATING METABOLIC FUNCTION OF XENOBIOTIC AND INDUCTION THEREOF | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-05-23 | — | — | WO | disclosed |
| WO-2002017926-A1 | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING HYPOGONADISM | UNIMED PHARMACEUTICALS, INC. (US) | 2002-03-07 | — | — | WO | disclosed |
| US-6274118-B1 | INJECTING PATIENT HAVING ENDOCRINE CANCER IN NON-PROSTATIC TISSUE WITH BIOLOGICAL BINDING UNITS WHICH BIND TO PROSTATE SPECIFIC ANTIGEN PRODUCED BY NON-PROSTATIC TISSUE | NORDION INTERNATIONAL INC. (CA) | 2001-08-14 | — | — | US | disclosed |
| US-6203813-B1 | OPIATE ANTAGONIST, STEROIDAL ANTIINFLAMMATORY AGENT AND CARRIER; SUSTAINED RELEASE; DRUG ABUSE TREATMENT | GOOBERMAN, LANCE L. | 2001-03-20 | — | — | US | disclosed |
| EP-0953340-A1 | Use of starch as active for the treatment or prevention of the signs of skin aging in a cosmetic or dermatological composition | L'OREAL (FR) | 1999-11-03 | — | — | EP | disclosed |
| EP-0934743-A1 | Use of a wax microdispersion in cosmetic or dermatological compositions | L'OREAL (FR) | 1999-08-11 | — | — | EP | disclosed |
| EP-0723775-B1 | Use of dehydroepi-androsterone in cosmetic or dermatologic composition | OREAL (FR) | 1997-12-10 | — | — | EP | disclosed |
| EP-0758229-A1 | TOPICAL POLYMERIC DRUG DELIVERY SYSTEM | MERCK FROSST CANADA INC. (CA) | 1997-02-19 | — | — | EP | disclosed |
| EP-0723775-A1 | Use of dehydroepi-androsterone in cosmetic or dermatologic composition | L'OREAL (FR) | 1996-07-31 | — | — | EP | disclosed |
| WO-1995030409-A1 | TOPICAL POLYMERIC DRUG DELIVERY SYSTEM | MERCK FROSST CANADA INC. (CA) | 1995-11-16 | — | — | WO | disclosed |
| WO-1995002424-A1 | LOCALIZATION AND THERAPY OF NON-PROSTATIC ENDOCRINE CANCER WITH AGENTS DIRECTED AGAINST PROSTATE SPECIFIC ANTIGEN | NORDION INTERNATIONAL INC. (CA) | 1995-01-26 | — | — | WO | disclosed |
| CN-1026001-C | New esters of alginic acid | FIDIA SPA (IT) | 1994-09-28 | — | — | CN | disclosed |
| EP-0391503-B1 | Preparation of 7 beta-hydroxy-4-pregnene-3,20-dione derivatives | SNOW BRAND MILK PRODUCTS CO LTD (JP) | 1994-06-15 | — | — | EP | disclosed |
| EP-0168277-B2 | POLY(ORTHOESTER)POLYMERS CONTAINING PENDANT ACID FUNCTIONALITIES AND LABILE BACKBONE BONDS | Merck & Co., Inc. (US) | 1992-12-30 | — | — | EP | disclosed |
| US-5028722-A | From acremonium fungi, intermediates for progesterones, ovulation inhibitors | SNOW BRAND MILK PRODUCTS CO., LTD. (JP) | 1991-07-02 | — | — | US | disclosed |
| EP-0391503-A2 | Preparation of 7 beta-hydroxy-4-pregnene-3,20-dione derivatives | SNOW BRAND MILK PRODUCTS CO. LTD. (JP) | 1990-10-10 | — | — | EP | disclosed |
| US-4772554-A | Ova fertilization assay | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1988-09-20 | — | — | US | disclosed |
| US-4765973-A | Polymers containing pendant acid functionalities and labile backbone bonds | MERCK & CO., INC. (US) | 1988-08-23 | — | — | US | disclosed |
| CN-87104499-A | Novel alginic acid esters | — | 1988-04-06 | — | — | CN | disclosed |
| US-4639366-A | Polymers containing pendant acid functionalities and labile backbone bonds | MERCK & CO., INC. (US) | 1987-01-27 | — | — | US | disclosed |
| EP-0168277-A1 | Poly(orthoester)polymers containing pendant acid functionalities and labile backbone bonds | MERCK & CO. INC. (US) | 1986-01-15 | — | — | EP | disclosed |
| EP-0147479-A1 | A water and drug delivery system for suppository use | MERCK & CO. INC. (US) | 1985-07-10 | — | — | EP | disclosed |
| US-4489056-A | SUSTAINED RELEASE | MERCK & CO., INC. (US) | 1984-12-18 | — | — | US | disclosed |
| EP-0003341-B1 | 11,17-SUBSTITUTED PREGNANES, THEIR PREPARATION AND APPLICATION FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS | SCHERING AKTIENGESELLSCHAFT (DE) | 1984-06-27 | — | — | EP | disclosed |
| EP-0108231-A1 | Biocatalyst | SCHERING AKTIENGESELLSCHAFT (DE) | 1984-05-16 | — | — | EP | disclosed |
| US-4439194-A | WAXY COATINGS AND CORES | MERCK & CO., INC. (US) | 1984-03-27 | — | — | US | disclosed |
| EP-0100424-A2 | Acid anhydrides as rate controlling agent for the erosion of polymers which latter polymers have beneficial substances dispersed throughout their matrix or where the polymer matrix surrounds the beneficial substance | MERCK & CO. INC. (US) | 1984-02-15 | — | — | EP | disclosed |
| EP-0014991-B1 | MICROBIOLOGICAL METHOD FOR THE PREPARATION OF 7-ALPHA-HYDROXYLATED STEROIDS | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1983-01-19 | — | — | EP | disclosed |
| US-4178361-A | Sustained release pharmaceutical composition | UNION CORPORATION (US) | 1979-12-11 | — | — | US | disclosed |
| EP-0003519-A1 | 17-Substituted steroids of the pregnane series, their preparation and their application | SCHERING AKTIENGESELLSCHAFT (DE) | 1979-08-22 | — | — | EP | disclosed |
| EP-0003519-A1 | 17-Substituted steroids of the pregnane series, their preparation and their application | SCHERING AKTIENGESELLSCHAFT (DE) | 1979-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277201-A1 | Use of hydroxyprogesterone derivatives for enhancing health and physical performance | HSD17B11, HSD17B1, CYP19A1 | CYP3A4 83/4885LMNA 2630/4885SMN1; SMN2 1147/4885 |
| US-20040010119-A1 | Novel proteins and nucleic acids encoding same | SNRPE, DNASE1L3, PABPC4 | CYP3A4 4884/4885LMNA 1095/4885SMN1; SMN2 831/4885 |
| US-20190038637-A1 | Use of Hydroxyprogesterone Derivatives for Enhanced Health and Physical Performance II | HSD17B11, HSD17B2, HSD17B1 | CYP3A4 88/4885LMNA 2511/4885SMN1; SMN2 1022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.